{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:39:31Z","timestamp":1790026771512,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08CA280388"],"award-info":[{"award-number":["K08CA280388"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA292075"],"award-info":[{"award-number":["R37CA292075"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lineberger Comprehensive Cancer Center Core Support Grant","award":["P30CA016086"],"award-info":[{"award-number":["P30CA016086"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1245\/s10434-025-17906-5","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T16:10:37Z","timestamp":1752941437000},"page":"9767-9775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictors of Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Selena J.","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Hong Ngoc Che","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris B.","family":"Agala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara G.","family":"Abdou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Selfridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-0178","authenticated-orcid":false,"given":"Philip M.","family":"Spanheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"issue":"2","key":"17906_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10549-016-4006-6","volume":"160","author":"M Golshan","year":"2016","unstructured":"Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016;160(2):297\u2013304. https:\/\/doi.org\/10.1007\/s10549-016-4006-6.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"17906_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1245\/s10434-020-08593-5","volume":"28","author":"O Petruolo","year":"2021","unstructured":"Petruolo O, Sevilimedu V, Montagna G, Le T, Morrow M, Barrio AV. How often does modern neoadjuvant chemotherapy downstage patients to breast-conserving surgery? Ann Surg Oncol. 2021;28(1):287\u201394. https:\/\/doi.org\/10.1245\/s10434-020-08593-5.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"17906_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med."},{"issue":"22","key":"17906_CR4","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med."},{"key":"17906_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07494-5","author":"CHNC Thai","year":"2024","unstructured":"Thai CHNC, An SJ, Haase CR, Selfridge JM, Agala CB, Spanheimer PM. Differential prognostic value of residual nodal burden in breast cancer subtypes. Breast Cancer Res Treat. 2024. https:\/\/doi.org\/10.1007\/s10549-024-07494-5.","journal-title":"Breast Cancer Res Treat."},{"issue":"28","key":"17906_CR6","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414\u201322. https:\/\/doi.org\/10.1200\/JCO.2007.10.6823.","journal-title":"J Clin Oncol."},{"issue":"4","key":"17906_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaoncol.2015.4935","volume":"2","author":"SS Mougalian","year":"2016","unstructured":"Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol. 2016;2(4):508\u201316. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4935.","journal-title":"JAMA Oncol."},{"issue":"27","key":"17906_CR8","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.21.00934","volume":"39","author":"M Brackstone","year":"2021","unstructured":"Brackstone M, Baldassarre FG, Perera FE, et al. Management of the axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol. 2021;39(27):3056\u201382. https:\/\/doi.org\/10.1200\/JCO.21.00934.","journal-title":"J Clin Oncol."},{"issue":"2","key":"17906_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1245\/s10434-017-6263-y","volume":"25","author":"Z Al-Hilli","year":"2018","unstructured":"Al-Hilli Z, Hoskin TL, Day CN, Habermann EB, Boughey JC. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol. 2018;25(2):482\u201393. https:\/\/doi.org\/10.1245\/s10434-017-6263-y.","journal-title":"Ann Surg Oncol."},{"key":"17906_CR10","doi-asserted-by":"publisher","unstructured":"Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML; EUBREAST Group. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg. 2021;156(6):e210891. https:\/\/doi.org\/10.1001\/jamasurg.2021.0891","DOI":"10.1001\/jamasurg.2021.0891"},{"issue":"3","key":"17906_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201364. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827.","journal-title":"J Clin Oncol."},{"issue":"4","key":"17906_CR12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):608\u201316. https:\/\/doi.org\/10.1097\/SLA.0000000000000924.","journal-title":"Ann Surg."},{"issue":"5","key":"17906_CR13","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1245\/s10434-015-5052-8","volume":"23","author":"EJ Diego","year":"2016","unstructured":"Diego EJ, McAuliffe PF, Soran A, et al. Axillary staging after neoadjuvant chemotherapy for breast cancer: a pilot study combining sentinel lymph node biopsy with radioactive seed localization of pre-treatment positive axillary lymph nodes. Ann Surg Oncol. 2016;23(5):1549\u201353. https:\/\/doi.org\/10.1245\/s10434-015-5052-8.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"17906_CR14","doi-asserted-by":"publisher","first-page":"e235834","DOI":"10.1001\/jamanetworkopen.2023.5834","volume":"6","author":"S Shubeck","year":"2023","unstructured":"Shubeck S, Zhao F, Howard FM, Olopade OI, Huo D. Response to treatment, racial and ethnic disparity, and survival in patients with breast cancer undergoing neoadjuvant chemotherapy in the US. JAMA Netw Open. 2023;6(3):e235834. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.5834.","journal-title":"JAMA Netw Open."},{"issue":"4","key":"17906_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","volume":"268","author":"OM Fayanju","year":"2018","unstructured":"Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018;268(4):591\u2013601. https:\/\/doi.org\/10.1097\/SLA.0000000000002953.","journal-title":"Ann Surg."},{"issue":"10","key":"17906_CR16","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.1245\/s10434-022-12191-y","volume":"29","author":"JC Boughey","year":"2022","unstructured":"Boughey JC, Hoskin TL, Day CN, Goetz MP. Nodal pathologic complete response rates in luminal breast cancer vary by genomic risk. Ann Surg Oncol. 2022;29(10):6254\u201364. https:\/\/doi.org\/10.1245\/s10434-022-12191-y.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"17906_CR17","doi-asserted-by":"publisher","first-page":"e233329","DOI":"10.1001\/jamanetworkopen.2023.3329","volume":"6","author":"F Zhao","year":"2023","unstructured":"Zhao F, Miyashita M, Hattori M, et al. Racial disparities in pathological complete response among patients receiving neoadjuvant chemotherapy for early-stage breast cancer. JAMA Netw Open. 2023;6(3):e233329. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.3329.","journal-title":"JAMA Netw Open."},{"issue":"5","key":"17906_CR18","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/SLA.0000000000006135","volume":"279","author":"AG Telonis","year":"2024","unstructured":"Telonis AG, Rodriguez DA, Spanheimer PM, Figueroa ME, Goel N. Genetic ancestry-specific molecular and survival differences in admixed patients with breast cancer. Ann Surg. 2024;279(5):866\u201373. https:\/\/doi.org\/10.1097\/SLA.0000000000006135.","journal-title":"Ann Surg."},{"issue":"2","key":"17906_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/jnci\/djx135","volume":"110","author":"MA Troester","year":"2018","unstructured":"Troester MA, Sun X, Allott EH, et al. Racial differences in PAM50 subtypes in the Carolina breast cancer study. J Natl Cancer Inst. 2018;110(2):176\u201382. https:\/\/doi.org\/10.1093\/jnci\/djx135.","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"17906_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1245\/s10434-016-5600-x","volume":"24","author":"P Whitworth","year":"2017","unstructured":"Whitworth P, Beitsch P, Mislowsky A, Pellicane JV, Nash C, Murray M, Lee LA, Dul CL, Rotkis M, Baron P, Stork-Sloots L, de Snoo FA, Beatty J. Chemosensitivity and endocrine sensitivity in clinical luminal breast cancer patients in the prospective neoadjuvant breast registry symphony trial (NBRST) predicted by molecular subtyping. Ann Surg Oncol. 2017;24(3):669\u201375. https:\/\/doi.org\/10.1245\/s10434-016-5600-x.","journal-title":"Ann Surg Oncol."},{"issue":"19","key":"17906_CR21","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","volume":"19","author":"H Masuda","year":"2013","unstructured":"Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533\u201340. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0799.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"17906_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-018-4909-5","volume":"172","author":"AK Green","year":"2018","unstructured":"Green AK, Aviki EM, Matsoukas K, Patil S, Korenstein D, Blinder V. Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2018;172(2):247\u201363. https:\/\/doi.org\/10.1007\/s10549-018-4909-5.","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"17906_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41523-018-0059-5","volume":"20","author":"KC Foy","year":"2018","unstructured":"Foy KC, Fisher JL, Lustberg MB, Gray DM, DeGraffinreid CR, Paskett ED. Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white women. NPJ Breast Cancer. 2018;20(4):7. https:\/\/doi.org\/10.1038\/s41523-018-0059-5.","journal-title":"NPJ Breast Cancer."},{"key":"17906_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2019.112494","volume":"239","author":"BC Miller","year":"2019","unstructured":"Miller BC, Bowers JM, Payne JB, Moyer A. Barriers to mammography screening among racial and ethnic minority women. Soc Sci Med. 2019;239:112494. https:\/\/doi.org\/10.1016\/j.socscimed.2019.112494.","journal-title":"Soc Sci Med."},{"issue":"2","key":"17906_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1158\/1055-9965.EPI-22-0692","volume":"32","author":"X Hu","year":"2023","unstructured":"Hu X, Kaplan CM, Martin MY, et al. Race differences in patient-reported symptoms during chemotherapy among women with early-stage hormone receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev. 2023;32(2):167\u201374. https:\/\/doi.org\/10.1158\/1055-9965.EPI-22-0692.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"11","key":"17906_CR26","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/cncr.30575","volume":"123","author":"MK Yee","year":"2017","unstructured":"Yee MK, Sereika SM, Bender CM, Brufsky AM, Connolly MC, Rosenzweig MQ. Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer. Cancer. 2017;123(11):2061\u20139. https:\/\/doi.org\/10.1002\/cncr.30575.","journal-title":"Cancer."},{"issue":"14","key":"17906_CR27","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA."},{"issue":"7","key":"17906_CR28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery [published correction appears in JAMA Surg. 2017 Jul 1;152(7):708]. JAMA Surg. 2017;152(7):665\u201370. https:\/\/doi.org\/10.1001\/jamasurg.2017.0562.","journal-title":"JAMA Surg."},{"issue":"10","key":"17906_CR29","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094.","journal-title":"J Clin Oncol."},{"issue":"4","key":"17906_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12609-019-00330-6","volume":"11","author":"JK Jang","year":"2019","unstructured":"Jang JK, Sverdlik ER, Schechter NR. A radiation oncologist\u2019s guide to axillary management in breast cancer: a walk through the trials [published correction appears in Curr Breast Cancer Rep. 2020 Mar;12(1):44. 10.1007\/s12609-020-00352-5]. Curr Breast Cancer Rep. 2019;11(4):293\u2013302. https:\/\/doi.org\/10.1007\/s12609-019-00330-6.","journal-title":"Curr Breast Cancer Rep."},{"issue":"25","key":"17906_CR31","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2108873.","journal-title":"N Engl J Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17906-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17906-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17906-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:18:56Z","timestamp":1762352336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17906-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":31,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["17906"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17906-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}